Pfizer CEO Albert Bourla has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing that his ...

The three major Hong Kong stock indices weakened collectively. By the close, the Hang Seng Index fell 0.08% to 24,162.87, the Tech Index dropped 0.76% to 5,392.19, and the HSCEI declined 0.15% to ...

Two drugs. Two strategies. One industry in the middle of a rewiring.

Jefferies reaffirms its Buy rating on Pfizer and sticks to a $33 target, calling the stock undervalued at $23.35. Their ...

BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...

Under terms of the deal, both companies will co-develop and co-commercialize BNT327 for multiple solid tumors, with the ...

Meanwhile, BioNTech itself bought into the category with its takeover of BNT327's developer Biotheus unit last year for what ...

A colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

The US’s policy under the Second Donald Trump Administration has undergone major changes, with experts saying that America is ...

Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of ...

Per the terms of the deal, Pfizer will acquire the rights to develop and market SSGJ-707 -- an investigational cancer medicine -- worldwide, except in China. The pharmaceutical giant dished out an ...